Almakki Health Informatics Journal

Harnessing Artificial Intelligence in Generic Formulation Development and Life Cycle Management - A Comprehensive Review

Murali Mohan Babu[1], Ni Luh Putu Nurshanti[2], Harry Martha Wijaya[3], Raymond R. Tjandrawinata[4*]
Dexa Development Center, Indonesia[1,2,3]
Atma Jaya Catholic University of Indonesia, Indonesia[4]
E-mail: raymond@dexa-medica.com

KEYWORDS	ABSTRACT
Artificial Intelligence (AI); generic drugs; pharmaceutical development; development cycle; pharmaceutical industry.	Artificial intelligence (AI) is revolutionizing the pharmaceutical industry by enhancing efficiency, precision, and cost-effectiveness in drug development. This study explores the application of AI in the lifecycle management of generic drugs, focusing on key stages such as active pharmaceutical ingredient (API) synthesis, excipient selection, pre-formulation studies, bioequivalence testing, and regulatory compliance. By leveraging machine learning algorithms, AI facilitates predictive modeling, risk assessment, and optimization of drug formulation processes, reducing time-to-market and improving scalability. Despite significant advancements, challenges such as data quality, algorithm transparency, and infrastructure limitations persist, particularly in resource-constrained settings. This review highlights case studies and emerging technologies that address these challenges, providing actionable insights for pharmaceutical stakeholders. The study also discusses AI's potential to streamline supply chain logistics, enhance accessibility, and ensure regulatory adherence. By integrating AI across all stages of generic drug development, this research underscores its transformative potential in improving drug affordability, accessibility, and patient outcomes globally.

INTRODCUTION

Artificial intelligence is a swiftly progressing domain that holds the potential to transform our way of living and working. AI systems can execute tasks that conventionally demand human intellect by emulating human intelligence processes like learning, reasoning, and self-correction. From autonomous vehicles and speech recognition to medical diagnosis and personalized shopping recommendations, the utilization of AI is varied and extensive. AI can process and scrutinize substantial volumes of data at an unparalleled pace, enabling more efficient and precise decision-making (Avrahami & Korchatov, 2019; Ghosh & Singh, 2020)

AI has already accomplished considerable advancements in multiple domains, such as healthcare, education, finance, network security, and social media. Within healthcare, AI promises to revolutionize patient care through improved diagnosis and treatment (Dave & Patel, 2023). For instance, AI can recognize patterns and signals in medical images, leading to earlier identification of diseases like cancer (Fogel & Kvedar, 2018; He et al., 2019; Kamruzzaman, 2020; Malik et al., 2019; Rong et al., 2020) Moreover, AI can analyze extensive amounts of patient data to aid in creating personalized treatment plans and predicting patient outcomes. AI can individualize learning experiences in the education sector by analyzing student data and adjusting instructional materials accordingly.

Furthermore, AI plays a critical role in finance by automating tasks such as risk assessment and fraud detection. In network security, AI can improve threat detection and

response by examining large volumes of data for anomalies or patterns indicating cyberattacks. AI algorithms analyze user behavior and preferences for targeted advertising and personalized content recommendations within social media platforms. The impact of deep English on addressing societal issues & improving global well-being is significant (Zhai et al., 2021). The potential of AI in various sectors is undeniable, and its impact continues to grow. Artificial Intelligence has become a pervasive and transformative technology in today's society.

Advances in AI have significantly impacted various industries, driving innovation and efficiency. AI has led to breakthroughs in medical imaging analysis, drug discovery, and personalized treatment plans in healthcare. For instance, Massachusetts Institute of Technology researchers have developed an AI model that can predict breast cancer five years in advance with 31% more accuracy than traditional methods. This has the potential to revolutionize early detection and improve patient outcomes (Kamruzzaman, 2020), (Lee & Yoon, 2021), (Shen et al., 2023)

In finance, AI detects fraudulent activities, optimizes trading strategies, and provides personalized financial advice. Companies like JP Morgan Chase have implemented AI systems to analyze complex financial data and improve decision-making processes. This has not only enhanced security measures but also streamlined operations and reduced costs (Shen et al., 2023)

In manufacturing, predictive maintenance powered by artificial intelligence transformed the industry by enabling proactive equipment maintenance while minimizing downtime and optimizing production processes for substantial cost savings as well as improved overall productivity (Coandă et al., 2020), (ElFar et al., 2021)).

This review delves into a comprehensive overview of artificial intelligence (AI), exploring its diverse branches and applications across various sectors, including the pharmaceutical industry. Furthermore, it intricately details the methodology involved in generic product development, elucidating the strategic utilization of AI at each stage of the process. These stages encompass product selection procedures, patent assessments, selection of excipients, and studies on drug-excipient compatibility. Additionally, the review expounds on the role of AI in pre-formulation activities, analytical method development, formulation processes, process development, scaling-up procedures, commercial manufacturing endeavors, bioequivalence studies, and regulatory strategies within the realm of generic drug development.

Numerous studies have demonstrated the transformative role of artificial intelligence (AI) in the pharmaceutical industry. For example, Bannigan et al. (2021) highlighted the effectiveness of AI-driven machine learning algorithms in optimizing drug formulation development, reducing time-to-market while ensuring high-quality outcomes. Similarly, Kolluri et al. (2022) explored the role of AI in biorelevant dissolution methods and pre-formulation studies, showcasing its ability to predict drug-excipient interactions with high precision. Another study by Mak and Pichika (2019) underscored AI's potential in streamlining bioequivalence studies and enhancing the scalability of manufacturing processes. These studies collectively demonstrate AI's growing impact across various stages of drug development, particularly in improving efficiency and cost-effectiveness. However,

there remains a gap in research addressing the comprehensive integration of AI throughout the lifecycle of generic drugs, from development to post-market surveillance.

Although artificial intelligence (AI) has shown promising applications in pharmaceutical development, its implementation in generic drug lifecycle management remains underexplored. Most studies focus on AI's role in new drug discovery or specific stages of development, such as formulation and testing. However, there is limited research on integrating AI across the entire lifecycle of generic drugs, from formulation development to post-market surveillance. Additionally, the potential of AI to address challenges in regulatory compliance, cost reduction, and scalability in resource-limited settings has not been fully investigated.

This study introduces a comprehensive framework for leveraging AI in the end-to-end development and lifecycle management of generic drugs. Unlike previous studies that focus on isolated applications of AI, this research explores its holistic integration, including excipient compatibility, predictive modeling for bioequivalence, and automated regulatory documentation. Furthermore, the study incorporates an analysis of AI's potential to optimize supply chain logistics and improve accessibility in underserved markets, offering novel insights into its transformative capabilities in the pharmaceutical industry.

The primary objective of this study is to evaluate the integration of AI in the entire lifecycle of generic drug development, identifying its impact on efficiency, cost reduction, and regulatory compliance. The research aims to develop strategies for implementing AI-driven solutions to enhance formulation development, process optimization, and market accessibility. The findings will benefit pharmaceutical companies by streamlining operations, reducing time-to-market, and improving product affordability. Additionally, policymakers and healthcare providers can leverage these insights to enhance drug availability and affordability, ultimately improving patient outcomes globally.

RESEARCH METHOD

This research utilizes a literature review approach, which studies the complex intersection between artificial intelligence (AI) methodologies and the complex landscape of generic drug development. The research begins with an in-depth understanding of the characteristics of generic drugs, including active ingredients, dosage forms, strength, and mode of administration. The authors conducted a market analysis to identify generic drug development needs and trends. Data collection includes a review of scientific literature, relevant patents, as well as interviews with experts in pharmaceuticals and drug development, to gain comprehensive insights. Furthermore, the article analyzes AI applications in each stage of generic drug development, from excipient selection to compatibility studies and analytical method development. The authors also review case studies to assess the impact of using AI in the process.

RESULT AND DISCUSIION
Detailed Methodology of Development of Generic Formulations
Understanding Generic Formulations: An Overview

Understanding Generic Formulations: A generic drug can be described as a pharmaceutical that acts as a substitute for a previously introduced medication, containing the same active ingredient, dosage form, strength, and method of administration as the original branded product. The development process for generic drugs involves extensive research and

testing to ensure their safety and effectiveness when used as intended. A key goal of generic drugs is to offer more affordable options compared to branded medications without compromising on efficacy or safety (Peters et al., n.d; - et al., 2023, (J. R. Peters et al., 2009), (Administration, 2018), (Mulcahy et al., 2022), (Rana & Roy, 2015), (Brems et al., 2011)

The global generic drugs market projects a staggering valuation of US$474 billion by 2023, characterized by a compound annual growth rate (CAGR) of 10.4% over the forecast period. This market surge is propelled by the escalating need for cost-effective healthcare solutions, the prevalence of chronic ailments, and the uptick in approvals for generic drug formulations. The market delineation by distribution channel unveils retail pharmacies as the predominant player, commanding a lion's share exceeding 60%, trailed by hospitals at slightly over 20%. In contrast, online pharmacies are poised for rapid expansion, currently capturing a portion exceeding 10%. Geographically, North America leads the charge in the generic drugs domain, securing a substantial share exceeding 40%, closely pursued by Europe at over 30%. In stark contrast, Asia-Pacific emerges as the burgeoning region, with its market slice surpassing the 20% mark and showcasing remarkable growth potential.

The primary factors propelling the global generic drugs market are the escalating requirement for cost-effective healthcare, the increasing incidence of chronic ailments, and a growing number of approvals for generic drugs. The surging demand for affordable healthcare is fueling the expansion of the worldwide generic drugs market. Generic drugs typically cost less than branded medications, making them more appealing to consumers. Moreover, the prevalence of chronic diseases such as diabetes, cancer, and heart conditions is on an upward trajectory, triggering a heightened need for generic drugs to treat these health issues. Furthermore, the mounting approvals for generic drug products also drive growth within the global domain. Governments across diverse nations are progressively endorsing these medications to enhance consumer accessibility.

This upsurge can be attributed to their economical nature and improved availability, which positively contribute to delivering healthcare services effectively. While enterprises focusing on innovating pharmaceuticals emphasize research and development initiatives, generics make significant contributions by providing economical healthcare alternatives that augment access to necessary medicines, especially for disadvantaged communities globally.

The dynamics governing this sector involve compassionate concerns intertwined with corporate objectives. Its mission centers on offering cost-efficient remedies while complying rigorously with regulatory standards and ethical considerations. Organizations like WHO and USP play pivotal roles in empowering developing countries' regulatory frameworks by setting forth guidelines addressing manufacturing practices and quality controls along enhanced public access routes. Numerous local accrediting bodies incessantly strive toward outperforming international benchmarks, ensuring safety outcomes, and maintaining stringent quality parameters at each stage from raw materials procurement to reach end users, compels manufacturers to balance income stream whilst adhering comprehensively strict product inspection measures throughout the supply chain continuum efficiently even operational revenue margins remain meager (- et al., 2023, (Gangone et al., 2017), Research, 2018; Global Generic Drugs Market to Reach US$ 474 Billion by 2023, 2018)

Figure 1. Generic product development cycle

Exploring the Methodology of Generic Drug Development

The formulation of generic medications is a sophisticated and multidimensional process encompassing scientific, regulatory, and economic intricacies. A comprehensive methodology for creating generic formulations can be outlined to elaborate on this.

Scientific aspects of the process involve identifying viable alternatives to the active pharmaceutical ingredient found in the branded medication, carefully selecting appropriate excipients, and formulating a product that matches the bioequivalence of the original drug. Additionally, choosing container-closure systems is a critical consideration in developing generic products. From a regulatory standpoint, the procedure includes submitting an Abbreviated New Drug Application to the pertinent regulatory bodies, backed by data that substantiates the safety and efficacy of the proposed generic formulation. Economic factors are significant, encompassing research and development expenses, manufacturing, marketing, and distribution of generic medications. The complete generic product development cycle illustrated in Fig. 2

In conclusion, while developing generic formulations is indispensable for increasing access to cost-effective healthcare solutions, it remains a complex and arduous process fraught with scientific, regulatory, and economic hurdles that must be navigated to achieve successful outcomes.

Scientific Complexities

In scientific complexities, the rigorous process of developing generic formulations demands a deep understanding of the intricate interplay between pharmaceutical ingredients, excipients, and delivery systems.

Formulation development complexities

Formulation development complexities include the selection of appropriate quality active pharmaceutical ingredient, excipients, and their combinations, which are thoroughly assessed to achieve the desired drug delivery system based on international standards or pharmacopeial references such as USP or EP monographs exceptionally meeting the standards of elemental impurities, Genotoxic impurities, nitrosamines, Ethylene glycol, and Diethylene glycol, etc. Additionally, the selection of container closure systems is also pivotal while developing the primary pack of formulation in the light of leachable & extractable, and Nitrosamines. Furthermore, the physicochemical properties of the drug substance, such as

solubility, stability, and bioavailability, must be carefully considered to design a formulation that can achieve the desired therapeutic effect (- et al., 2023). Based on drug substance properties, selection of excipients/composition, and manufacturing process that can replicate the therapeutic effects of the original drug. The scientific complexities also extend to the challenges in conducting comprehensive pre-formulation studies, where a deep understanding of individual drug components' physical and chemical properties is essential. Techniques such as differential scanning calorimetry or X-ray powder diffraction are indispensable tools in this development phase, allowing for a thorough analysis of the drug's characteristics. Scientists must always pay attention to the importance of dissolution method and specification while developing formulation because they play a critical role in ensuring the drug's effectiveness and safety. The variability in dissolution rates between the generic formulation and its reference-listed drug requires meticulous attention to detail to achieve bioequivalence.

Bioequivalence studies complexities

Bioequivalence studies are complex and encompass the meticulous planning and execution of clinical trials to demonstrate the therapeutic equivalence of generic formulations compared to reference-listed drugs. These studies require careful consideration of multiple factors, including sample size, study design, patient demographics, and statistical analysis, to ensure robust evidence of bioequivalence. Moreover, selecting appropriate analytical methods is crucial to accurately measuring drug concentrations and assessing pharmacokinetic parameters. Achieving bioequivalence for drug substances belonging to Biopharmaceutics Classification System Class 3 & 4 is intricate and often requires additional measures such as conducting comparative pharmacokinetic studies as pilot BE studies or assessing in vitro-in vivo correlation.

The ever-evolving scientific landscape and technological advancements present continuous challenges for pharmaceutical researchers who seek to refine their approach to formulation development while maintaining stringent quality and safety standards. In conclusion, developing generic formulations involves a comprehensive understanding of the target drug's pharmacokinetic properties, formulation attributes, and physiological implications (Haidar et al., 2008).

Manufacturing process development complexities

Manufacturing complexities in generic production necessitate the meticulous optimization of the manufacturing process to guarantee product uniformity, robust process, and reproducibility on a substantial scale (Haidar et al., 2008). This intricate task involves strict adherence to Current Good Manufacturing Practices (cGMP) guidelines, which meticulously regulate the manufacturing processes to ensure that generic drugs adhere to similarly stringent safety, efficacy, and quality standards outlined for the reference listed drug. Numerous factors like sourcing raw materials, manufacturing facility capabilities and qualification, equipment calibration, packaging equipment calibration and capabilities, and personnel training require stringent oversight to maintain consistency and excellence in manufacturing practices. Additionally, implementing advanced manufacturing technologies and automation adds complexity, demanding a balance between innovation and regulatory compliance.

Regulatory Complexities

Regulatory complexities in generic formulation development are multifaceted and have wide-ranging effects on the pharmaceutical industry. The need to navigate intricate patent laws, intellectual property rights, and regulatory submission processes poses significant hurdles for companies engaged in generic drug development. Additionally, the evolving regulatory landscape at both international and local levels requires pharmaceutical companies to stay abreast of changing guidelines and standards, adding layers of complexity to the development and approval of generic formulations.

Addressing these complexities in generic formulation development requires a concerted effort from pharmaceutical companies, regulatory bodies, and healthcare providers to ensure that essential medicines remain accessible and affordable to individuals and communities worldwide. This involves a commitment to ongoing research and development, adherence to regulatory standards, and the continued pursuit of cost-effective manufacturing practices without compromising quality and safety. Various scientific techniques and methods, such as PK (pharmacokinetics) studies, toxicity assessments, and biopharmaceutical properties evaluation, are employed

Logistic complexities:

Logistic complexities in generic formulation development arise from establishing a robust supply chain infrastructure (Saillot & Paxton, 2009). This includes sourcing raw materials, ensuring quality control throughout the manufacturing process, and managing distribution logistics to ensure timely availability of the generic formulation in the market (Ghosh Chaudhuri & Paria, 2012). Recently, covid outbreak has further highlighted the importance of logistics in ensuring the uninterrupted supply of essential medicines to patients.

Economic Complexities

Economic complexities are inherent to developing generic formulations, particularly concerning cost-effective manufacturing processes and financial viability. Balancing the imperative of offering cost-efficient remedies with the substantial investments required for robust research, development, and regulatory compliance presents a formidable challenge for pharmaceutical companies. Moreover, the competitive nature of the generic drug market and the influence of pricing mechanisms further compound the economic intricacies associated with formulation development.

In light of these multifaceted complexities, the pharmaceutical industry is propelled to address these challenges through innovation, collaboration, and a global commitment to enhancing the accessibility and affordability of essential generic medications. Moreover, fostering a supportive regulatory environment and advocating for policies that incentivize investment in generic drug development are crucial steps in overcoming the current complexities and expanding access to vital medicines for all individuals and communities in need.

AI applications in Generic Pharmaceutical Industry

The pharmaceutical research industry faces numerous challenges in the rapidly changing global landscape. Introducing new drugs requires significant time and resources, presenting obstacles to their market entry. Developing generic drugs is a lengthy, costly

process with high failure rates. However, artificial intelligence has the potential to revolutionize these processes by enhancing efficiency, precision, and cost-effectiveness. AI algorithms can efficiently analyze large data sets and identify patterns that may be overlooked. This article comprehensively reviews how AI shapes both basic and complex aspects of generic drug development.

AI applications in generic drug formulation development

Artificial intelligence (AI) is transforming generic drug development in numerous ways. Here are some key applications of AI in the generics industry:

I.   AI applications in active pharmaceutical ingredient synthesis

Active pharmaceutical ingredients (APIs) form the foundational elements of pharmaceutical drugs, pivotal for instigating their therapeutic efficacy. The synthesis of APIs embodies a sophisticated and demanding procedure that mandates a significant degree of precision and accuracy. In recent years, the advent of artificial intelligence (AI) has emerged as a formidable asset, offering the potential to enhance the efficiency and precision in the synthesis of APIs.

AI-powered technologies can be incredibly valuable for automating various steps in the API synthesis process, including designing reaction pathways, selecting reaction conditions, and optimizing reaction parameters. Additionally, AI can play a critical role in identifying and mitigating potential risks associated with API synthesis, such as impurity formation and API degradation. The use of AI in API synthesis has the potential to significantly improve the efficiency, accuracy, and safety of the API synthesis process. This could lead to the development of new and more effective drugs, and the reduction of the cost of drug production. Some of the specific applications of AI in API synthesis include:

1. The use of AI-powered technologies to design reaction pathways for the synthesis of new APIs

The utilization of AI-driven technologies in devising reaction pathways for generating novel APIs has witnessed noteworthy progress. Ravitz (Mergendoller et al., 2013) and (Funatsu, 1988)delve into the utilization of predictive tools for synthetic route forecasting, with the latter introducing the AIPHOS system that amalgamates synthesis blueprinting and reaction anticipation. Johansson (Johansson et al., 2019), offers an exhaustive examination of AI models for predicting synthesis, encompassing retro-synthesis strategizing and forward synthesis projection. Coley (Coley et al., 2019) advanced this by merging a retrosynthesis projection algorithm with a robotically reconfigurable flow system for streamlined synthesis. Baumann (Baumann & Baxendale, 2015) and Yu et al., (Feng et al., 2017), underline the merits of uninterrupted flow chemistry and constituent-centered synthesis within this realm. Lastly, (Gasteiger et al., 1992) and Gasteiger (Gasteiger et al., 1992), elaborate on diverse computerized techniques for synthesis scheming and reaction anticipation, with a specific emphasis on the EROS system and its use in formulating organic syntheses.

2. The use of AI to select the optimal reaction conditions for the synthesis of APIs

Several investigations have delved into the application of AI in enhancing reaction conditions for the synthesis of APIs. Fitzpatrick (Fitzpatrick et al., 2016) and Nunn (Nunn et al., 2018), each showcased the effective utilization of AI in determining optimal

conditions for specific APIs, with Fitzpatrick's research particularly emphasizing the potential for remote server-based optimization. Clayton (Clayton et al., 2020) and Sahoo (Sahoo et al., 2023), further elaborated on this concept by integrating AI with self-optimizing platforms and algorithm-driven design of experiments, respectively. Emenike (Emenike et al., 2018) and Wan (Wan et al., 2021), concentrated on leveraging AI in reactor design and enzyme-driven synthesis, with Wan's study introducing a data-centric machine learning model for forecasting optimal conditions. Funatsu (Funatsu, 1988) and Gao (Gao et al., 2021), offered historical and contemporary perspectives on AI systems for designing organic synthesis and predicting reactions, with Gao's research specifically honing in on employing a neural network model for forecasting suitable conditions.

3. The use of AI to identify and mitigate potential risks associated with API synthesis

The utilization of AI in API synthesis brings forth a myriad of possibilities and complexities. (Wacker et al., 2005), underscores the significance of pinpointing crucial process parameters and quality features, which can be facilitated through AI interventions. Conversely, Cummaudo (Cummaudo et al., 2020) alert against the potential perils linked to the evolution of intelligent web services, proposing adopting an architectural strategy to counterbalance these risks. Nam (Nam et al., 2022) and Liu (Liu et al., 2020) advocate for the application of machine learning to hasten program synthesis, with Nam concentrating on anticipatory synthesis and Liu delving into mining API utilization patterns. Werner (Werner et al., 2023) and Koessler (Koessler & Schuett, 2023) both delve into the necessity of resilient risk evaluation and management protocols in AI-infused systems, with Koessler specifically recommending the adoption of risk assessment methodologies from other safety-critical sectors.

II. Generic Product Development

AI effectively enhances every phase of Generic formulation development, beginning with selecting excipients, conducting API-excipient compatibility studies and preformulation research, and devising biorelevant dissolution methods. It also contributes to analytical method development, formulation creation, process upscaling, and commercial manufacturing for generic drug formulation while ensuring stability, bioavailability, and patient compliance. Through analyzing formulation data and leveraging multivariate analysis for predictions, AI can facilitate the development of resilient and economical formulations for generic products (Aksu et al., 2012; Allen & Bannigan, 2019; Bannigan et al., 2021; Dong et al., 2021; Gao et al., 2021; Han et al., 2018; Khalid & Usman, 2021; Kolluri et al., 2022; Mak & Pichika, 2019; J. L. Peters et al., 1992; Vora et al., 2023; Zawbaa et al., 2018; Zhao & Truhlar, 2006)

Other applications of AI

1. Drug Repurposing

AI-driven drug repurposing approaches leverage existing data and knowledge to identify new therapeutic uses for generic drugs. By analyzing large biomedical datasets and identifying novel connections between drugs and diseases, AI can expedite the discovery of new indications for existing generic medications.

The utilization of artificial intelligence (AI) in the arena of drug repurposing displays substantial promise in the identification of potential drug candidates for a range

of ailments, encompassing conditions such as COVID-19 and cancer (Dotolo et al., 2021; Farghali et al., 2021; Mohanty et al., 2020; Selvaraj et al., 2021; Tanoli et al., 2021; Urbina et al., 2021; Zhou et al., 2020). AI has proven particularly adept in swift virtual screening, target forecasting, and drug repositioning, expediting drug discovery and development processes with enhanced speed and efficacy. Despite the requirement for expanded data resources, AI has showcased its capacity to hasten drug repurposing initiatives and unearthing novel therapeutic options for intricate human diseases.

2. Patient Data Analysis

AI technologies are employed to analyze patient data, including electronic health records and clinical trial data, to identify trends, predict outcomes, and personalize treatment regimens. This personalized approach to generic drug prescribing can improve patient outcomes and reduce healthcare costs. In recent years, the progression of AI applications in analyzing patient data has been notable, with a specific emphasis on enhancing the effectiveness of medical practitioners (Бурсов, 2019), Бурсов, 2019). Nevertheless, obstacles persist, including intricate and noisy datasets and the necessity for elucidating AI outputs (Altman, 2017)AI has exhibited marked advantages in realms such as drug development, clinical trials, and patient care, particularly in the intensive care setting, where it can decrease expenses and enhance patient outcomes (Hanson III & Marshall, 2001). The examination of patient trajectories through AI has been under scrutiny, offering prospects for personalized risk assessment and the discovery of disease pathways (Allam et al., 2021). AI applications have been instrumental in scrutinizing medical images, forecasting disease progression, and bolstering clinical decision-making processes (Fatima et al., 2023)Proposals have surfaced on integrating IoT sensors with AI to elevate patient support and care standards (Fouad et al., 2020). Moreover, within the realm of dentistry, AI and data science have been instrumental in diagnosing Temporomandibular joint Osteoarthritis (Bianchi et al., 2021).

Limitations and challenges of AI in Generic Drug Development

The incorporation of artificial intelligence (AI) into the domain of generic formulation development and the pharmaceutical manufacturing industry presents a plethora of advantages, though concurrently introduces a series of intricate challenges necessitating careful consideration and resolution. A prominent concern stems from the intricacy and variability inherent in pharmaceutical formulations. AI algorithms encounter difficulties in navigating the complex interplay and distinguishing characteristics among diverse drug components, potentially leading to inaccuracies in predictive outcomes and formulation optimizations. The heterogeneous nature of raw materials, manufacturing methodologies, and quality standards further complicates matters, posing a formidable obstacle for AI systems to consistently yield precise and reliable results. Another formidable challenge pertains to the availability and quality of data necessary for AI operations. The efficacy of AI algorithms crucially hinges on access to extensive, high-caliber datasets for training and validation purposes. Within the pharmaceutical industry, acquiring comprehensive and trustworthy datasets is often hindered by proprietary constraints, regulatory limitations, and data privacy considerations. These constraints on diverse and representative data availability may impede the efficacy of AI applications in developing generic drugs. Moreover, the interpretability of

AI-driven determinations presents a substantial barrier. In an industry as critical as pharmaceuticals, where adherence to regulatory standards is of paramount importance, the comprehension of the rationale behind AI-derived conclusions holds significant weight. The opacity of certain AI models complicates the ability of researchers, regulators, and stakeholders to comprehend and corroborate the outputs, potentially obstructing the widespread acceptance and utilization of AI tools in formulation development and manufacturing operations.

Furthermore, concerns remain about the scalability and integration of AI systems with current manufacturing infrastructures. Successfully integrating AI technologies into current manufacturing equipment, procedures, and workflows demands substantial investments in infrastructure, education, and validation processes. Assuring the compatibility and reliability of AI solutions across diverse manufacturing sites and protocols poses an ongoing challenge for the industry.

In summary, while AI presents many opportunities to enhance generic formulation development and pharmaceutical manufacturing, it is crucial to address the complex issues related to formulation complexity, data authenticity, interpretability, and seamless integration. Successfully overcoming these challenges is essential to fully harnessing the transformative potential of AI in the pharmaceutical sector. Taking proactive steps to mitigate these issues will be key to utilizing the powerful capabilities of AI to advance generic drug development and production processes.

Probable solutions to address the challenges related to AI in generic drug development and manufacturing

In order to tackle the complexities inherent in integrating artificial intelligence (AI) into the realms of generic formulation development and pharmaceutical manufacturing, a plethora of potential solutions can be posited:

Improving Data Accessibility and Quality: Foster collaborative efforts among stakeholders to promote data sharing, focusing on maintaining data privacy and confidentiality. Allocate resources to standardize data and improve its quality, ensuring the availability of comprehensive datasets for training and validating AI systems.

Increasing Transparency and Interpretability of Algorithms: Prioritize developing transparent AI models that provide clear insights into decision-making processes, boosting confidence levels and facilitating adherence to regulatory requirements. Establish methods for thorough model documentation and verification to help researchers, regulators, and stakeholders understand the outcomes produced by AI systems.

Advancing Training in AI: Implement specialized training programs tailored for pharmaceutical professionals to deepen their understanding and use of AI technologies in formulation development and manufacturing processes. In addition, foster collaboration between AI experts, pharmacologists, and manufacturing specialists to refine AI algorithms according to the specific complexities of pharmaceutical formulations.

Adapting Infrastructure for Scalability: Conduct comprehensive assessments of existing manufacturing infrastructures to identify opportunities for integrating and optimizing AI technologies. Invest in improving infrastructure capabilities while modernizing technologies necessary for seamless integration across various manufacturing facilities.

Compliance with Regulatory Standards: Establish collaborative partnerships with regulatory bodies to create frameworks governing AI implementation in pharmaceutical manufacturing, ensuring compliance with standards while strengthening data security protocols through regular audits and adapting systems based on evolving regulations.

Monitoring Performance Effectively: Implement rigorous monitoring mechanisms designed to assess how effectively AI applications are used within formulation and process development. This will help pharmaceutical manufacturing undertake routine examinations, leading to refinement in operational processes and continual improvement within the pharmaceutical sector.

By executing these solutions, the pharmaceutical industry can surmount the challenges entwined with AI integration, thereby harnessing the transformative potential of artificial intelligence to foster innovation, efficiency, and excellence in the sphere of generic drug development and pharmaceutical manufacturing.

Future developments of AI in generic formulation development

The prospective outlook of artificial intelligence (AI) applications in generic formulation development portrays promising advancements and transformative capabilities poised to revolutionize the pharmaceutical sector. Below delineates forthcoming developments and trends in AI within this sphere:

1. Personalized Formulation: AI algorithms are anticipated to steer the creation of personalized generic formulations that cater to individual patient requirements. Leveraging patient data, genetic insights, and real-time health metrics, AI is set to facilitate the customization of dosage strengths, delivery mechanisms, and formulations optimized for effectiveness and patient adherence.

2. Prognostic Formulation Design: AI-driven predictive modeling is anticipated to expedite the design and enhancement of generic formulations. Through the analysis of extensive datasets, machine learning algorithms will predict formulation outcomes, pinpoint optimal drug combinations, and streamline the formulation development process, consequently reducing time-to-market for generic drugs.

3. Automated Drug Discovery:AI is primed to play a crucial role in hastening drug discovery for generic formulations by pinpointing novel drug candidates and repurposing existing drugs for novel therapeutic applications. Deep learning algorithms will aid in identifying potential drug targets, thereby boosting the efficiency and cost-effectiveness of drug discovery endeavors.

4. Optimized Processes: AI-powered analytics and integration with the Internet of Things (IoT) will refine manufacturing processes for generic formulations. Real-time monitoring by AI algorithms will detect manufacturing parameter deviations, recommend adjustments to boost efficiency, curtail wastage, and ensure product quality and uniformity.

5. Regulatory Adherence: AI is poised to streamline regulatory compliance initiatives in generic formulation development by automating documentation tasks, monitoring regulatory changes, and ensuring alignment with quality standards. AI-driven compliance systems are projected to expedite approvals, diminish regulatory uncertainties, and bolster overall compliance management within the pharmaceutical domain.

6. Synergetic Research Platforms: AI-facilitated collaborative platforms are envisioned to foster knowledge-sharing and cooperation among researchers, pharmaceutical entities, and regulatory entities in the realm of generic formulation development. These platforms will facilitate real-time data exchange, virtual collaborations, and insights sharing to foster innovation and quicken drug development processes.

7. Virtual Clinical Trials: AI simulations and virtual patient modeling are forecasted to enable the execution of virtual clinical trials for generic formulations. Researchers can optimize clinical trial designs, prophesize outcomes, and tailor treatment plans by employing AI to simulate drug responses in virtual populations. This leads to heightened efficiency and cost-effectiveness in drug development endeavors.

To conclude, the forthcoming advancements of AI in generic formulation development harbor immense potential to enhance drug efficacy, expedite development timelines, refine manufacturing processes, and ensure regulatory conformity. Through the utilization of AI technologies, the pharmaceutical sector stands on the verge of achieving substantial progress in formulating and manufacturing generic drugs, ultimately benefiting patients globally by bolstering healthcare outcomes and enhancing access to affordable medications.

CONCLUSION

The conclusion of this study shows that the application of AI in generic drug development has great potential to improve efficiency, accuracy, and cost. AI can accelerate active ingredient identification and excipient selection, as well as formulation development through rapid and in-depth data analysis. In addition, AI helps overcome existing challenges in generic drug development, such as compatibility issues and risks associated with synthesizing active ingredients. Thus, the application of AI not only improves the quality and safety of generic drug formulations, but also supports better drug accessibility for the public. Overall, this article confirms that the integration of AI in generic drug development can be a strategic solution in dealing with the complexity of the pharmaceutical industry, encouraging innovation and accelerating the development process while maintaining high quality standards.

REFERENCES

Administration, U. S. F. and D. (2018). Drug approvals and databases. *Retrived from: Http://Www. Fda. Gov/Drugs/InformationOnDrugs/Default. Htm.*

Aksu, K., Donmez, A., & Keser, G. (2012). Inflammation-induced thrombosis: mechanisms, disease associations and management. *Current Pharmaceutical Design*, *18*(11), 1478–1493.

Allam, A., Feuerriegel, S., Rebhan, M., & Krauthammer, M. (2021). Analyzing patient trajectories with artificial intelligence. *Journal of Medical Internet Research*, *23*(12), e29812.

Allen, C., & Bannigan, P. (2019). Does artificial intelligence have the potential to transform drug formulation development? In *Journal of Controlled Release* (Vol. 311, pp. 326–327). Elsevier.

Altman, R. B. (2017). Artificial intelligence (AI) systems for interpreting complex medical datasets. *Clinical Pharmacology & Therapeutics*, *101*(5), 585–586.

Avrahami, A., & Korchatov, E. (2019). The Value of Inventory Accuracy in Supply Chain Management: Correlation Between Error Sources and Proactive Error Correction. *American Journal of Operations Management and Information Systems*, *4*(1), 1–15.

Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A., & Allen, C. (2021). Machine learning directed drug formulation development. *Advanced Drug Delivery Reviews*, *175*, 113806.

Baumann, M., & Baxendale, I. R. (2015). The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry. *Beilstein Journal of Organic Chemistry*, *11*(1), 1194–1219.

Bianchi, J., Ruellas, A., Prieto, J. C., Li, T., Soroushmehr, R., Najarian, K., Gryak, J., Deleat-Besson, R., Le, C., & Yatabe, M. (2021). Decision support systems in temporomandibular joint osteoarthritis: a review of data science and artificial intelligence applications. *Seminars in Orthodontics*, *27*(2), 78–86.

Brems, A., Baeyens, J., Beerlandt, J., & Dewil, R. (2011). Thermogravimetric pyrolysis of waste polyethylene-terephthalate and polystyrene: A critical assessment of kinetics modelling. *Resources, Conservation and Recycling*, *55*(8), 772–781.

Clayton, A. D., Schweidtmann, A. M., Clemens, G., Manson, J. A., Taylor, C. J., Niño, C. G., Chamberlain, T. W., Kapur, N., Blacker, A. J., & Lapkin, A. A. (2020). Automated self-optimisation of multi-step reaction and separation processes using machine learning. *Chemical Engineering Journal*, *384*, 123340.

Coandă, P., Avram, M., & Constantin, V. (2020). A state of the art of predictive maintenance techniques. *IOP Conference Series: Materials Science and Engineering*, *997*(1), 12039.

Coley, C. W., Thomas III, D. A., Lummiss, J. A. M., Jaworski, J. N., Breen, C. P., Schultz, V., Hart, T., Fishman, J. S., Rogers, L., & Gao, H. (2019). A robotic platform for flow synthesis of organic compounds informed by AI planning. *Science*, *365*(6453), eaax1566.

Cummaudo, A., Barnett, S., Vasa, R., Grundy, J., & Abdelrazek, M. (2020). Beware the evolving 'intelligent'web service! An integration architecture tactic to guard AI-first components. *Proceedings of the 28th ACM Joint Meeting on European Software Engineering Conference and Symposium on the Foundations of Software Engineering*, 269–280.

Dave, M., & Patel, N. (2023). Artificial intelligence in healthcare and education. *British Dental Journal*, *234*(10), 761–764.

Dong, J., Gao, H., & Ouyang, D. (2021). PharmSD: A novel AI-based computational platform for solid dispersion formulation design. *International Journal of*

Pharmaceutics, *604*, 120705.

Dotolo, S., Marabotti, A., Facchiano, A., & Tagliaferri, R. (2021). A review on drug repurposing applicable to COVID-19. *Briefings in Bioinformatics*, *22*(2), 726–741.

ElFar, O. A., Chang, C.-K., Leong, H. Y., Peter, A. P., Chew, K. W., & Show, P. L. (2021). Prospects of Industry 5.0 in algae: Customization of production and new advance technology for clean bioenergy generation. *Energy Conversion and Management: X*, *10*, 100048.

Emenike, V. N., Schenkendorf, R., & Krewer, U. (2018). A systematic reactor design approach for the synthesis of active pharmaceutical ingredients. *European Journal of Pharmaceutics and Biopharmaceutics*, *126*, 75–88.

Farghali, H., Canová, N. K., & Arora, M. (2021). The potential applications of artificial intelligence in drug discovery and development. *Physiological Research*, *70*(Suppl 4), S715.

Fatima, I., Grover, V., Khan, I. R., Ahmad, N., & Yadav, A. (2023). Artificial Intelligence in Medical Field. *EAI Endorsed Transactions on Pervasive Health and Technology*, *9*.

Feng, Y., Martins, R., Wang, Y., Dillig, I., & Reps, T. W. (2017). Component-based synthesis for complex APIs. *Proceedings of the 44th ACM SIGPLAN Symposium on Principles of Programming Languages*, 599–612.

Fitzpatrick, D. E., Battilocchio, C., & Ley, S. V. (2016). A novel internet-based reaction monitoring, control and autonomous self-optimization platform for chemical synthesis. *Organic Process Research & Development*, *20*(2), 386–394.

Fogel, A. L., & Kvedar, J. C. (2018). Artificial intelligence powers digital medicine. *NPJ Digital Medicine*, *1*(1), 5.

Fouad, H., Hassanein, A. S., Soliman, A. M., & Al-Feel, H. (2020). Analyzing patient health information based on IoT sensor with AI for improving patient assistance in the future direction. *Measurement*, *159*, 107757.

Funatsu, H. (1988). A note on the stability of the Harris-Todaro model with capital mobility. *Economica*, 119–121.

Gangone, S., Godala, D., & Kashetti, S. V. (2017). A review of pharmacoeconomics and a discussion on branded, branded generics and generics. *Pharmacoeconomics*, *2*(2), 1–5.

Gao, M., Liu, S., Chen, J., Gordon, K. C., Tian, F., & McGoverin, C. M. (2021). Potential of Raman spectroscopy in facilitating pharmaceutical formulations development–an AI perspective. *International Journal of Pharmaceutics*, *597*, 120334.

Gasteiger, H. A., Frederick, W. J., & Streisel, R. C. (1992). Solubility of aluminosilicates in alkaline solutions and a thermodynamic equilibrium model. *Industrial & Engineering Chemistry Research*, *31*(4), 1183–1190.

Ghosh Chaudhuri, R., & Paria, S. (2012). Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. *Chemical Reviews*, *112*(4), 2373–2433.

Ghosh, S., & Singh, A. (2020). The scope of Artificial Intelligence in mankind: A detailed review. *Journal of Physics: Conference Series*, *1531*(1), 12045.

Haidar, S. H., Davit, B., Chen, M.-L., Conner, D., Lee, L., Li, Q. H., Lionberger, R., Makhlouf, F., Patel, D., & Schuirmann, D. J. (2008). Bioequivalence approaches for highly variable drugs and drug products. *Pharmaceutical Research*, *25*, 237–241.

Han, R., Yang, Y., Li, X., & Ouyang, D. (2018). Predicting oral disintegrating tablet formulations by neural network techniques. *Asian Journal of Pharmaceutical Sciences*, *13*(4), 336–342.

Hanson III, C. W., & Marshall, B. E. (2001). Artificial intelligence applications in the intensive care unit. *Critical Care Medicine*, *29*(2), 427–435.

He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019). The practical implementation of artificial intelligence technologies in medicine. *Nature Medicine*, *25*(1), 30–36.

Johansson, S., Thakkar, A., Kogej, T., Bjerrum, E., Genheden, S., Bastys, T., Kannas, C., Schliep, A., Chen, H., & Engkvist, O. (2019). AI-assisted synthesis prediction. *Drug Discovery Today: Technologies*, *32*, 65–72.

Kamruzzaman, M. M. (2020). Architecture of smart health care system using artificial intelligence. *2020 IEEE International Conference on Multimedia & Expo Workshops (ICMEW)*, 1–6.

Khalid, G. M., & Usman, A. G. (2021). Application of data-intelligence algorithms for modeling the compaction performance of new pharmaceutical excipients. *Future Journal of Pharmaceutical Sciences*, *7*, 1–11.

Koessler, L., & Schuett, J. (2023). Risk assessment at AGI companies: A review of popular risk assessment techniques from other safety-critical industries. *ArXiv Preprint ArXiv:2307.08823*.

Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: a review. *The AAPS Journal*, *24*, 1–10.

Lee, D., & Yoon, S. N. (2021). Application of artificial intelligence-based technologies in the healthcare industry: Opportunities and challenges. *International Journal of Environmental Research and Public Health*, *18*(1), 271.

Liu, B., Lai, M., Wu, J.-L., Fu, C., & Binaykia, A. (2020). Patent analysis and classification prediction of biomedicine industry: SOM-KPCA-SVM model. *Multimedia Tools and Applications*, *79*, 10177–10197.

Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*, *24*(3), 773–780.

Malik, P., Pathania, M., & Rathaur, V. K. (2019). Overview of artificial intelligence in medicine. *Journal of Family Medicine and Primary Care*, *8*(7), 2328–2331.

Mergendoller, J. R., Markham, T., Ravitz, J., & Larmer, J. (2013). Pervasive management of project-based learning: Teachers as guides and facilitators. In *Handbook of classroom management* (pp. 593–626). Routledge.

Mohanty, S., Rashid, M. H. A., Mridul, M., Mohanty, C., & Swayamsiddha, S. (2020). Application of Artificial Intelligence in COVID-19 drug repurposing. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *14*(5), 1027–1031.

Mulcahy, A., Buttorff, C., Finegold, K., El-Kilani, Z., Oliver, J. F., Murphy, S., & Jessup, A. (2022). Projected US savings from biosimilars, 2021-2025. *American Journal of Managed Care*, *28*(7).

Nam, D., Ray, B., Kim, S., Qu, X., & Chandra, S. (2022). Predictive synthesis of api-centric code. *Proceedings of the 6th ACM SIGPLAN International Symposium on Machine Programming*, 40–49.

Nunn, C., DiPietro, A., Hodnett, N., Sun, P., & Wells, K. M. (2018). High-throughput automated design of experiment (DoE) and kinetic modeling to aid in process development of an API. *Organic Process Research & Development*, *22*(1), 54–61.

Peters, J. L., Schreuder, M. E. L., Verduin, S. J. W., & Kendrick, R. E. (1992). Physiological characterization of a high-pigment mutant of tomato. *Photochemistry and Photobiology*, *56*(1), 75–82.

Peters, J. R., Hixon, D. R., Conner, D. P., Davit, B. M., Catterson, D. M., & Parise, C. M. (2009). Generic drugs–safe, effective, and affordable. *Dermatologic Therapy*, *22*(3), 229–240.

Rana, P., & Roy, V. (2015). Generic medicines: issues and relevance for global health. *Fundamental & Clinical Pharmacology*, 29(6), 529–542.

Rong, G., Mendez, A., Assi, E. B., Zhao, B., & Sawan, M. (2020). Artificial intelligence in healthcare: review and prediction case studies. *Engineering*, 6(3), 291–301.

Sahoo, J., Gunupuru, R., Sairam, P. S., & Ravulakollu, K. K. (2023). Machine Learning Process for Synthesizing Optimum Amount of Pharmaceuticals Ingredients. *2023 10th International Conference on Computing for Sustainable Global Development (INDIACom)*, 367–372.

Saillot, J.-L., & Paxton, M. (2009). Industry efforts on simultaneous global development. *Drug Information Journal: DIJ/Drug Information Association*, 43, 339–347.

Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D.-Q. (2021). Application of artificial intelligence in drug repurposing: A mini-review. *Current Chinese Science*, 1(3), 333–345.

Shen, X., Wu, J., Su, J., Yao, Z., Huang, W., Zhang, L., Jiang, Y., Yu, W., & Li, Z. (2023). Revisiting artificial intelligence diagnosis of hepatocellular carcinoma with DIKWH framework. *Frontiers in Genetics*, 14, 1004481.

Tanoli, Z., Vähä-Koskela, M., & Aittokallio, T. (2021). Artificial intelligence, machine learning, and drug repurposing in cancer. *Expert Opinion on Drug Discovery*, 16(9), 977–989.

Urbina, F., Puhl, A. C., & Ekins, S. (2021). Recent advances in drug repurposing using machine learning. *Current Opinion in Chemical Biology*, 65, 74–84.

Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, 15(7), 1916.

Wacker, D. P., Berg, W. K., Harding, J. W., Barretto, A., Rankin, B., & Ganzer, J. (2005). Treatment effectiveness, stimulus generalization, and acceptability to parents of functional communication training. *Educational Psychology*, 25(2–3), 233–256.

Wan, Z., Wang, Q.-D., Liu, D., & Liang, J. (2021). Accelerating the optimization of enzyme-catalyzed synthesis conditions via machine learning and reactivity descriptors. *Organic & Biomolecular Chemistry*, 19(28), 6267–6273.

Werner, B. D., Schumeg, B. J., Mills, T. M., & Bott, D. M. (2023). Roadmap Development to Reduce Risk Associated with the Deployment of Artificial Intelligence Enabled Systems. *2023 Annual Reliability and Maintainability Symposium (RAMS)*, 1–6.

Zawbaa, H. M., Schiano, S., Perez-Gandarillas, L., Grosan, C., Michrafy, A., & Wu, C.-Y. (2018). Computational intelligence modelling of pharmaceutical tabletting processes using bio-inspired optimization algorithms. *Advanced Powder Technology*, 29(12), 2966–2977.

Zhai, X., Chu, X., Chai, C. S., Jong, M. S. Y., Istenic, A., Spector, M., Liu, J.-B., Yuan, J., & Li, Y. (2021). A Review of Artificial Intelligence (AI) in Education from 2010 to 2020. *Complexity*, 2021(1), 8812542.

Zhao, Y., & Truhlar, D. G. (2006). A new local density functional for main-group thermochemistry, transition metal bonding, thermochemical kinetics, and noncovalent interactions. *The Journal of Chemical Physics*, 125(19).

Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. *The Lancet Digital Health*, 2(12), e667–e676.

Бурсов, А. И. (2019). Применение искусственного интеллекта для анализа медицинских данных. *Альманах Клинической Медицины*, 47(7), 630–633.